Condition in which irregular and rapid heart rate results in poor blood supply to the body is referred as arterial fibrillation (AF). In this condition, the atrial chambers do not beat in coordination with ventricles of heart. Atrial fibrillation shows symptoms such as rapid and irregular heart rate, palpitation, weakness, exercise intolerance, edema, shortness of breath and sometimes angina symptoms. Atrial fibrillation is classified based on symptoms such as first detected atrial fibrillation where only one episode is diagnosed, paroxysmal atrial fibrillation where recurrent episodes and self terminate in less than seven days, persistent atrial fibrillation where episodes are recurrent and last more than seven days and permanent atrial fibrillation where long term occurrence of episode takes place. Though atrial fibrillation is commonly associated with cardiac diseases, healthy heart can also suffer atrial fibrillation. Cardiac diseases linked to atrial fibrillation include, hypertension, mitral stenosis, coronary artery disease and congenital heart diseases. In addition lung diseases such as lung cancer, sarcoidosis, pneumonia, asthma, diabetes and heavy alcohol consumption are some of the other conditions that may result in atrial fibrillation. Family history of atrial fibrillation is another major factor that increases the disease risk in a person.
Specialists involved in the diagnosis of atrial fibrillation are cardiologists, electrophysiologists and primary care physicians. Based on the method of diagnosis, the global atrial fibrillation diagnostics market is segmented as follows:
Based on the type of diagnostic catheters used, global atrial fibrillation (AF) diagnostics market is classified as follows:
Factors such as aging of population and sedentary life style resulting in rapidly increasing prevalence of cardiac diseases worldwide are driving the growth of the global atrial fibrillation diagnostics market. On the other hand, high cost involved in diagnosis of atrial fibrillation on the grounds of high equipment costs and scarce availability of diagnostic facilities is restraining the growth of atrial fibrillation diagnostics market. As atrial fibrillation diagnostic tools are costly, reprocessed diagnostic catheters market shows growth potential.
Geographically, the global atrial fibrillation diagnostics market is segmented as follows:
North America is dominating the global atrial fibrillation diagnostics market and is followed by Europe. Factors driving the growth of atrial fibrillation diagnostics market in North America and Europe include high awareness about atrial fibrillation diagnostic tools, well defined reimbursement framework, highly developed healthcare infrastructure and higher healthcare spending. Asia-Pacific is a lucrative market for global atrial fibrillation diagnostics due to increasing healthcare spending and rapidly increasing awareness about the diseases. In addition, countries namely, India and China in Asia Pacific region will attract cross-country patients due to rapidly growing medical tourism industry in these countries. Some of the major companies contributing to global atrial fibrillation diagnostics market are Becton, Dickinson & Company, Medtronic Inc., Boston Scientific Corp., Sanofi-Aventis, Zimmer Holdings Inc., St. Jude Medical Inc., Baxter International, Inc. and AtriCure Inc.